2.18
price up icon1.40%   0.03
after-market Handel nachbörslich: 2.15 -0.03 -1.38%
loading
Schlusskurs vom Vortag:
$2.15
Offen:
$2.15
24-Stunden-Volumen:
1.17M
Relative Volume:
1.03
Marktkapitalisierung:
$154.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-192.96M
KGV:
-0.7786
EPS:
-2.8
Netto-Cashflow:
$-167.04M
1W Leistung:
-8.79%
1M Leistung:
+3.81%
6M Leistung:
-55.05%
1J Leistung:
-86.01%
1-Tages-Spanne:
Value
$2.14
$2.20
1-Wochen-Bereich:
Value
$2.10
$2.4302
52-Wochen-Spanne:
Value
$1.79
$15.80

Ventyx Biosciences Inc Stock (VTYX) Company Profile

Name
Firmenname
Ventyx Biosciences Inc
Name
Telefon
(858) 945-2393
Name
Adresse
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Name
Mitarbeiter
73
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
VTYX's Discussions on Twitter

Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-06-14 Fortgesetzt Credit Suisse Outperform
2023-03-21 Eingeleitet Wells Fargo Overweight
2022-12-19 Eingeleitet Goldman Buy
2022-11-17 Eingeleitet Morgan Stanley Overweight
2022-09-07 Eingeleitet Stifel Buy
2022-09-01 Eingeleitet H.C. Wainwright Buy
2022-05-09 Eingeleitet Credit Suisse Outperform
2022-03-31 Eingeleitet Canaccord Genuity Buy
2022-02-01 Eingeleitet Oppenheimer Outperform
2021-11-15 Eingeleitet Jefferies Buy
2021-11-15 Eingeleitet Piper Sandler Overweight
Alle ansehen

Ventyx Biosciences Inc Aktie (VTYX) Neueste Nachrichten

pulisher
03:30 AM

Vanguard Group Inc's Strategic Acquisition in Ventyx Biosciences Inc - GuruFocus.com

03:30 AM
pulisher
Nov 04, 2024

Ventyx Biosciences: Ready To Escape "The Crash Cycle" (NASDAQ:VTYX) - Seeking Alpha

Nov 04, 2024
pulisher
Oct 28, 2024

These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts - Markets Insider

Oct 28, 2024
pulisher
Oct 28, 2024

Brokerages Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $8.29 - MarketBeat

Oct 28, 2024
pulisher
Oct 17, 2024

HC Wainwright Cuts Earnings Estimates for Ventyx Biosciences - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

Ventyx Biosciences maintains Neutral rating from H.C. Wainwright - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 in Ulcerative Colitis at UEG Week 2024 - Marketscreener.com

Oct 16, 2024
pulisher
Oct 16, 2024

Ventyx Biosciences maintains Neutral rating from H.C. Wainwright By Investing.com - Investing.com UK

Oct 16, 2024
pulisher
Oct 16, 2024

Ventyx Biosciences Presents New 52-Week Results from the - GlobeNewswire

Oct 16, 2024
pulisher
Oct 15, 2024

Ventyx Biosciences (NASDAQ:VTYX) Given "Neutral" Rating at HC Wainwright - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

Ventyx reports positive Phase 2 ulcerative colitis trial data - Investing.com

Oct 15, 2024
pulisher
Oct 15, 2024

Ventyx reports positive Phase 2 ulcerative colitis trial data By Investing.com - Investing.com Canada

Oct 15, 2024
pulisher
Oct 15, 2024

VTYX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Oct 15, 2024
pulisher
Oct 15, 2024

Ventyx Biosciences Inc (VTYX) stock analysis: A comprehensive overview - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024 - The Manila Times

Oct 15, 2024
pulisher
Oct 08, 2024

Did Ventyx Biosciences Inc (VTYX) perform well in the last session? - US Post News

Oct 08, 2024
pulisher
Oct 07, 2024

An analyst sees good growth prospects for Ventyx Biosciences Inc (VTYX) - SETE News

Oct 07, 2024
pulisher
Oct 07, 2024

Sanofi Invests $27M in Ventyx Bio - San Diego Business Journal

Oct 07, 2024
pulisher
Oct 03, 2024

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Oct 03, 2024
pulisher
Oct 02, 2024

Ventyx Biosciences Inc (VTYX) may enjoy gains as insiders got busy in the recent days - Knox Daily

Oct 02, 2024
pulisher
Oct 02, 2024

Is Ventyx Biosciences Inc (VTYX) a good investment opportunity? - US Post News

Oct 02, 2024
pulisher
Sep 30, 2024

Gaining Ground: Ventyx Biosciences Inc (VTYX) Closes Lower at 2.31, Down -2.12 - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

Take off with Ventyx Biosciences Inc (VTYX): Get ready for trading - SETE News

Sep 30, 2024
pulisher
Sep 28, 2024

VTYX Stock Rises on Strategic Equity Investment Deal With SNY - MSN

Sep 28, 2024
pulisher
Sep 26, 2024

Deerfield Management Company L.P. Series C Buys 2,287,570 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - MarketBeat

Sep 26, 2024
pulisher
Sep 26, 2024

Stock Surge: Ventyx Biosciences Inc (VTYX) Closes at 2.39, Marking a -2.85 Increase/Decrease - The Dwinnex

Sep 26, 2024
pulisher
Sep 26, 2024

Ventyx Biosciences, Inc. (NASDAQ:VTYX) to Post FY2024 Earnings of ($2.13) Per Share, HC Wainwright Forecasts - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

Sanofi’s $27 Million Investment in Ventyx Biosciences - Global Legal Chronicle

Sep 25, 2024
pulisher
Sep 25, 2024

Adversity is less terrifying than hope: Ventyx Biosciences Inc (VTYX) - SETE News

Sep 25, 2024
pulisher
Sep 24, 2024

Ventyx Biosciences retains stock target, neutral rating despite Sanofi's $27M stake - Investing.com

Sep 24, 2024
pulisher
Sep 24, 2024

Benjamin F. Edwards & Company Inc. Buys 16,858 Shares of Twist Bioscience Co. (NASDAQ:TWST) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Ventyx gets $27 million investment from Sanofi - The Pharma Letter

Sep 24, 2024
pulisher
Sep 23, 2024

Ventyx deal a sign of Sanofi’s growing interest neuro-immunology? - BioCentury

Sep 23, 2024
pulisher
Sep 23, 2024

Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal - Pharmaceutical Technology

Sep 23, 2024
pulisher
Sep 23, 2024

Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences - MSN

Sep 23, 2024
pulisher
Sep 23, 2024

Ventyx Biosciences Inc (VTYX) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle

Sep 23, 2024
pulisher
Sep 23, 2024

Ventyx Biosciences (NASDAQ:VTYX) Stock Rating Reaffirmed by HC Wainwright - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Ventyx stock climbs 8% on $27M Sanofi investment - MSN

Sep 23, 2024
pulisher
Sep 23, 2024

Thoughtworks (NASDAQ:TWKS) Sees Large Volume Increase - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

VTYX’s Q2 earnings predictions: What the experts say - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Sanofi investment in Ventyx shows VTX3232 interest, says H.C. Wainwright - TipRanks

Sep 23, 2024
pulisher
Sep 23, 2024

Sanofi scoops negotiation rights to Ventyx obesity, Parkinson’s candidate for $27M - Fierce Biotech

Sep 23, 2024
pulisher
Sep 23, 2024

Victory Capital (NASDAQ:VCTR) Hits New 12-Month High at $56.29 - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Ventyx stock climbs 8% on $27M Sanofi investment (NASDAQ:VTYX) - Seeking Alpha

Sep 23, 2024
pulisher
Sep 23, 2024

Sanofi invests $27 million in Ventyx Biosciences By Investing.com - Investing.com India

Sep 23, 2024
pulisher
Sep 23, 2024

Ventyx Biosciences Shares Rise Premarket on Sanofi Investment - Marketscreener.com

Sep 23, 2024
pulisher
Sep 23, 2024

Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi - GlobeNewswire

Sep 23, 2024
pulisher
Sep 22, 2024

(TWST) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Sep 22, 2024
pulisher
Sep 22, 2024

How the (TVE) price action is used to our Advantage - Stock Traders Daily

Sep 22, 2024
pulisher
Sep 21, 2024

Seven Eight Capital LP Buys Shares of 22,269 Victory Capital Holdings, Inc. (NASDAQ:VCTR) - MarketBeat

Sep 21, 2024
pulisher
Sep 20, 2024

Ventyx Biosciences Repeat Insider Selling Not A Positive Indicator - Simply Wall St

Sep 20, 2024

Finanzdaten der Ventyx Biosciences Inc-Aktie (VTYX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Ventyx Biosciences Inc-Aktie (VTYX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Krueger Christopher W
CHIEF BUSINESS OFFICER
Apr 02 '24
Sale
5.40
1,651
8,921
284,999
Nuss John
CHIEF SCIENTIFIC OFFICER
Apr 02 '24
Sale
5.40
1,651
8,921
264,998
Mohan Raju
CEO AND PRESIDENT
Apr 02 '24
Sale
5.40
4,312
23,299
1,578,250
Auster Martin
CHIEF FINANCIAL OFFICER
Apr 02 '24
Sale
5.40
1,405
7,592
24,303
Krueger Christopher W
CHIEF BUSINESS OFFICER
Mar 28 '24
Option Exercise
0.00
4,531
0
286,650
Auster Martin
CHIEF FINANCIAL OFFICER
Mar 28 '24
Option Exercise
0.00
4,531
0
25,708
Mohan Raju
CEO AND PRESIDENT
Mar 28 '24
Option Exercise
0.00
11,843
0
1,582,562
Nuss John
CHIEF SCIENTIFIC OFFICER
Mar 28 '24
Option Exercise
0.00
4,531
0
266,649
Nuss John
Chief Scientific Officer
Dec 20 '23
Sale
2.12
17,628
37,334
262,118
Krueger Christopher W
Chief Business Officer
Dec 20 '23
Sale
2.12
5,293
11,210
282,119
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):